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Abstract
Background: Atrial fibrillation (AF) is the most common arrhythmia requiring treatment. High 
dose oral anti-arrhythmics may cardiovert some paroxysmal AF. This "pill in pocket" approach 
has allowed patients to treat themselves on an as needed basis. Pro-arrhythmic concerns have 
limited the usefulness of this approach to patients without structural heart disease.  Ranolazine is 
an anti-anginal agent, which inhibits abnormal late Na+ channel currents in cardiomyocytes and 
decreases sodium-calcium overload. Ranolazine is a potent inhibitor of after-depolarizations, 
which have been implicated in the initiation and propagation of AF. Because ranolazine has no 
known pro-arrhythmic effects, it could be useful as a safe "pill in the pocket" agent if it were 
effective in converting AF. We describe our experience using oral ranolazine to convert new or 
paroxysmal   AF.                                                                                    
Method: 2000 mg of ranolazine were administered to 18 patients with new (11 patients) or 
paroxysmal (7 patients) AF of at least 3, but not greater than 48 hours duration. Most patients 
(14) were in the hospital at the time ranolazine was administered. Age, sex, echocardiographic 
data, associated health conditions and structural heart disease were recorded. Successful 
conversion was defined as restoring sinus rhythm within 6 hours of ranolazine administration.    
Results:  All but 1 patient had some form of structural heart disease and all but 2 patients had 
left atrial enlargement. Thirteen of 18 patients converted to sinus rhythm. No pro-arrhythmic 
effects, hemodynamic instability, adverse rate effects, or perceived intolerance (other than 
constipation) were noted. The 72% conversion rate was comparable to other reported "pill in the 
pocket" protocols.                                                                                                           
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Conclusion: High dose oral ranolazine shows utility as a possible safe agent to convert new or 
paroxysmal   AF.  Lack   of  blinded   controls  and   small   numbers   limits  the  power   of  this 
observation.
Key words:  atrial fibrillation; ranolazine; conversion; anti-rhythmic therapy; anti-rhythmic 
agents
Introduction
Atrial fibrillation (AF) is the most common arrhythmia requiring treatment [1,2]. Transthoracic 
electrical cardioversion has remained the most effective method for terminating AF since its 
introduction over 4 decades ago [3]. Alternatively, some patients may convert to normal sinus 
rhythm with anti-arrhythmic therapy [4-13]. Pro-arrhythmic concerns and the lack of a safe anti-
arrhythmic agent have limited the usefulness of anti-arrhythmic therapy in the un-monitored 
setting [6,8,9,14,15]. In properly chosen patients high dose oral anti-arrhythmic agents may 
effectively cardiovert some patients with paroxysmal AF [10-13]. In this approach, up to 100% 
of the normal daily dose of propafenone or flecainide is given as a single oral dose to patients 
without structural heart disease [10-13]. This "pill in the pocket" approach has allowed these 
patients to effectively treat themselves on an as needed basis when AF occurs without the need 
to immediately seek medical attention or use anti-arrhythmic therapy on a chronic basis.      
In 1998, Haissaguerre et al demonstrated that atrial fibrillation (AF) may originate and be 
perpetuated from ectopic activity originating at the junction of the left atrium and pulmonary 
veins [16]. The electrophysiologic mechanisms responsible for the abnormal impulse activity 
have been the source of several investigations [17-23]. Recently it has been determined that 
triggered activity may be particularly important [19-23].                                     
Ranolazine is an anti-anginal agent, which inhibits normal and abnormal late Na+ channel 
current in the ventricle and peak Na+ channel current in the atrium [24-26]. By this inhibition, it 
affects intracellular calcium handling producing an energy sparing effect [24]. Ranolazine has 
also been shown to be a potent inhibitor of after depolarizations produced by a number of 
mechanisms [25-28]. As such, it could prove to be particularly useful in the treatment of AF. 
Indeed, in the holter monitor data from the MERLIN trial, ranolazine was associated with a 
reduction in a number or several arrhythmias, including new episodes of AF [29,30]. We have 
extended these observations to show that ranolazine can be successfully employed as an anti-
arrhythmic agent and can be particularity useful in atrial fibrillation [31,32].                                 
Since ranolazine is devoid of known pro-arrythmic effects and is well tolerated, it could prove to 
be an ideal agent for the "pill in the pocket" approach to AF if it were effective in converting 
patients with paroxysmal AF to sinus rhythm. The purpose of this report is to review our 
experience using single dose oral ranolazine as a means to facilitate conversion of AF to sinus 
rhythm with the possible consequence of a "pill in the pocket" approach to some AF using 
ranolazine. This was a retrospective analysis of our experience using ranolazine for this purpose. 
Institutional review board approval is not required for retrospective chart review.            
Study   Population                                                                                        
Eighteen patients with a known duration of AF of greater than 3 hours but less than 48 hours 
agreed to try oral ranolazine to convert their atrial fibrillation. Patients were informed that this 
was an "off label" use of ranolazine and its ability to convert  them to  sinus   rhythm   was 
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unknown. The age, sex, left ventricular ejection fraction (%), left atrial diameter (mm) and 
volume index (ml/m²) by echocardiography, and associated structural heart, and other health 
conditions were determined for most patients. The history of the AF problem (first recognized 
episode or paroxysmal) was also determined for each patient. Finally, the location of the first 
ranolazine treatment (home, office, hospital) was determined.                                           
The treatment with ranolazine consisted of the administration of 2000 mg of ranolazine as a 
single oral dose. This dose was chosen as it consisted of 100% of the usual maximal 
recommended daily dose of this agent, similar to the dosing rationale employed with high dose 
propafenone or flecainide [10-13]. The treatment was considered successful if the interval 
between administration of the drug and conversion to sinus rhythm was six hours or less and 
there were no observable side effects, such as symptomatic hypotension (systolic blood 
pressure,   80 mm Hg), symptomatic bradycardia after restoration of sinus rhythm, dyspnea, 
presyncope, syncope, or conversion to atrial flutter or atrial tachycardia [11].                              
Patients were excluded from consideration of this approach if they had a long QT interval, were 
on any other anti-arrhythmic agent other than beta or calcium channel blockers, had a history of 
second- or third-degree atrioventricular block, bradycardia-tachycardia syndrome (resting heart 
rate,   50 beats per minute).                                                                                      
Four patients with a history of paroxysmal AF were given the opportunity of using this approach 
for recurrent future AF episodes on a "pill in the pocket" basis.  Each was instructed to take the 
drug at least 10 minutes after any subsequent onset of palpitations. After the ingestion of the 
drug, a resting state (in a supine or sitting position) was recommended until the palpitations had 
stopped or at least six hours had passed [11]. These patients were contacted periodically to see if 
they continued to have episodes of AF and how they responded to "pill in the pocket" ranolazine. 
Patients were advised to contact the emergency room or our office if their palpitations had not 
ceased within 12 hours of ingestion of the drug, or if they had symptoms that had not occurred 
during   previous   arrhythmic   episodes   (e.g.,   intolerable   palpitations,   dyspnea,   syncope,   or 
presyncope).
Results
Fourteen patients were in the hospital when AF occurred. In these patients, AF was not present 
at the time of hospitalization but occurred during the course of treatment for other issues. One 
hospitalized patient was recruited immediately after he had failed electrical cardioversion for 
new AF. In 2 patients with a history of paroxysmal AF, the AF occurred in the outpatient setting 
and the patients called our facility with recurrent palpitations. These patients were brought to the 
office for treatment where the AF was confirmed by an electrocardiogram. Two patients were at 
home when ranolazine was administered, including the index case to be discussed in more detail. 
In 11 patients, the AF was their first recognized episode of AF. Seven others had a history of 
paroxysmal AF. Each patient was aware of their arrhythmia because of palpitations but were 
hemodynamically stable   (i.e., without symptoms such as dyspnea, presyncope, or syncope). 
Table 1 describes the clinical characteristics of the patients in which oral ranolazine was used to 
attempt to convert AF and the setting initially employed. Note the wide spectrum of associated 
medical   conditions   and   structural   heart   disease.   Fourteen   of   the   16   patients   in   which 
echocardiographic data was available, had left atrial enlargement as measured by an elevated left 
atrial volume index exceeding 26 ml/m². Although most of the patients were monitored at the 
time of first use, 2 patients were in the office during first dose administration and 2 patients were 
at home.
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Table 1: Clinical Characteristics of AF patients
AS: aortic stenosis, brad-tach syn: bradycardia-tachycardia   syndrome, CAD: coronary artery disease, CHF: 
congestive heart failure, COPD: chronic obstructive pulmonary disease, EF: ejection fraction, D: dofetilide, HTN: 
hypertension, LAD: left atrial diameter (mm), IWMI:  inferior wall myocardial infarction, LAE: left atrial 
enlargement, LAVI: left atrial volume index (ml/m²), LVH: left ventricular hypertrophy, MI: myocardial infarction, 
MS: mitral stenosis, MR: mitral insufficiency,   OSA: obstructive sleep apnea, R: ranolazine, RA: rheumatoid 
arthritis, RHD: rheumatic heart disease. S:sotalol.
Table 2 outlines the results of oral ranolazine therapy and current status of the patients. Thirteen 
of the 18 patients responded to this approach. Of the four patients who used it on an out patient 
"pill in the pocket" basis, 1 failed therapy and is now in chronic AF having also failed sotalol 
and dofetilide, 2 continue to use ranolazine as needed for AF episodes and the other returned to 
chronic ranolazine usage to prevent episodes of AF after using it successfully as a converting 
agents a few times times. The details of this patient and the significance to this study bear 
documentation:  Patient 1 (Table 1 and 2) had a history of difficult to control AF, which was 
originally classified as persistent AF. He had promptly failed both sotalol and dofetilide within 
days with rapid relapse into AF after cardioversion. Using ranolazine as an anti-arrhythmic 
agent, this patient was electrically cardioverted to sinus rhythm and remained in sinus rhythm for 
nearly 1 year on chronic ranolazine (1000mg twice a day) [32]. Because of cost issues, this 
patient stopped ranolazine without informing us. Within a short period of time he had developed 
recurrent AF manifest as recurrent palpitations similar to what had marked his AF symptoms in 
the past. This prompted him to resume his ranolazine by taking an "extra pill" (2000 mg). He did 
this a few times over the course of a couple of months before he informed us of this: each time 
using ranolazine as a conversion medication only. On each occasion 2000 mg of ranolazine 
would restore sinus rhythm within a few hours of the onset of his typical palpitations where as in 
the past only electrical cardioversion would restore sinus rhythm. Having repeatedly relapsed 
after stopping ranolazine, this patient has elected to resume chronic ranolazine therapy rather 
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than continue this "pill in the pocket" approach. Ranolazine has continued to maintain him in 
sinus rhythm.  
Table 2: Results of Oral Ranolazine on Atrial Fibrillation
AF: atrial fibrillation, DC Direct current, NSR: normal sinus rhythm
Ranolazine was very well tolerated in this setting. No patient experienced any cardiovascular side 
effects or worsening of AF symptoms. One patient, who continues to use it on a "pill in the 
pocket" basis notes problems with constipation for approximately 36 hours each time he uses this 
approach.  
Discussion
We found that 2000 mg of oral ranolazine, when administered as a single oral dose for paroxysmal 
or new onset AF was associated with a conversion rate to sinus rhythm in 13 of 18 patients (72%) 
within 6 hours of dose administration. The conversion rate we observed by six hours with 
ranolazine was similar to 6 to 8 hour conversion rate previously reported with high dose oral "Pill 
in the Pocket" propafenone or flecainide [10-13] and higher than the 39% placebo 8 hour 
conversion rate noted by Capucci et al [13]. This dose of ranolazine was not associated with 
adverse cardiovascular side effects and was very well tolerated. In none of those patients was oral 
ranolazine   associated   with   any   worsening   of   the   symptom   of   AF   prior   to   conversion.  
Our results should not seem surprising. Ranolazine has already been shown to suppress clinical 
episodes of AF [29,30,32]. In a canine model, ranolazine exhibits powerful use dependent effects 
on atrial refractory periods, which should give it anti-fibrillatory effects [26]. Additionally, 
ranolazine is a powerful inhibitor of trigged activity which may be an important mechanism 
underlying to initiation and potentiation of AF [19-23,25-28]. Finally the time course of the 
observation is consistent with our prior experience where we reported that ranolazine begins to 
have significant anti-arrhythmic effects within a couple of hours of administration [31].  
Limitations
The small number of patients in our report makes it essential that these observations be confirmed. 
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Additionally, this was a real life experience with ranolazine. Like all real life clinical decision 
making regarding anti-arrhythmic therapy, we gauged the effectiveness of ranolazine based the 
observed clinical response. It is possible that the amount of AF in the 2 patients who continue to 
use ranolazine on a "pill in the pocket basis" is underestimated due to the occurrence of 
asymptomatic AF. Because it was not placebo controlled we cannot rule out the possibility that 
some of these patients would have converted spontaneously within the 6 hours usually observed. 
Indeed it seems very likely that some would have [10-13]. Larger number of patients and 
appropriate blinding are clearly indicated. This observation serves as a useful pilot study 
demonstrating the feasibility of this approach.                                                                                   
In summary                                                                                                                                   
Ranolazine shows promise as an anti-arrhythmic agent for AF and may be useful to facilitate 
conversion of AF using a "Pill in the Pocket" approach. Given the apparent electrophysiologic 
safety of ranolazine and the ability to use it in patients with structure heart disease, such an 
approach could have enormous economic implications. Further investigations are warranted to 
explore this novel use for this medication.                                                                                    
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